Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study

ObjectiveHormone receptor (HR)-low/HER2-negative breast cancers (BCs) are more likely to be basal-like BCs, with similar molecular features and gene expression profiles to HR-negative (estrogen receptor <1% or negative and progesterone receptor <1% or negative) BCs. Recently, with the clinical...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jing Peng, Yue Hong, Qitong Chen, Feng Xu, Danhua Zhang, Jia Yao, Qiongyan Zou, Liqin Yuan, Lun Li, Qian Long, Liqiu Liao, Mingwen Liu, Xuan Liu, Shouman Wang, Wenjun Yi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-03-01
coleção:	Frontiers in Endocrinology
Assuntos:	breast cancer estrogen receptor progesterone receptor triple-negative breast cancer HR-low/HER2-negative breast cancer neoadjuvant chemotherapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1347762/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!